Sign in
Stories
Dupixent's Priority Review for EoE Treatment
Share
Advancements in Cancer Treatment and Mar...
Biosimilar Partnership in U.S.
Growing Markets for Pain Relief
ANJESO Drug Insight and Market Forecast
Arcutis' Roflumilast Partnership in Japa...
Axsome's FDA Setback Sparks Investigatio...
Overview
API
Dupixent's sBLA for treating EoE in children aged 1 to 11 has been accepted for FDA Priority Review, with a target action date of January 31, 2024.
Ask a question
How does Dupixent's approval for EoE treatment align with broader advancements in pediatric healthcare?
How might Dupixent's approval for EoE treatment impact the healthcare landscape for children?
What potential challenges might arise in the commercialization of Dupixent for children's EoE treatment?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jun 2023
Jul 2023
Aug 2023
Sep 2023
Coverage